Kent Mouw
@mouwlab
Followers
1K
Following
4K
Media
50
Statuses
346
Radiation oncology physician-scientist @danafarber @brighamwomens Associate Professor @harvardmed #DNArepair #bladdercancer #prostatecancer
Boston, MA
Joined January 2018
RT @BladderCancerUS: In @nlm_nih: Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer wi….
pmc.ncbi.nlm.nih.gov
Tumor gene alterations can serve as predictive biomarkers for therapy response. The nucleotide excision repair (NER) helicase ERCC2 carries heterozygous missense mutations in approximately 10% of...
0
2
0
RT @UroDocAsh: Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25!. Together we’ll focus on two cruci….
0
32
0
Finally, we compared our functional data to several computational predictors of pathogenicity. although helicase domain mutations were more likely to be predicted pathogenic, there were significant discrepancies, highlighting the important role of functional approaches.
0
0
3
Importantly, we also adapted the CRISPR-Select assay to introduce heterozygous ERCC2 mutations (how they occur in patients!) and show that these het ERCC2 mutations are sufficient to drive cisplatin sensitivity.
1
0
5
We validated and extended our previous findings that only mutations in the helicase domain sensitize to cisplatin.
1
0
1
Next, we applied a high-throughput CRISPR-based functional assay (CRISPR-Select) developed in the Sorensen lab to test the impact of ERCC2 mutations on cisplatin sensitivity.
nature.com
Nature Genetics - CRISPR-Select is a quantitative assay for the functional impact of genetic variants, including pathogenicity, drug response, oncogenicity, cell motility and other cell states.
1
0
1
We assembled a multi-institutional cohort of >2000 MIBCs and comprehensively mapped the ERCC2 mutational landscape. ERCC2 helicase domain mutations were assoc with improved survival in patients treated with neoadjuvant chemotherapy, but not in patients with metastatic dx.
1
0
2
First of all, this was a huge collaborative effort co-led by the Sorensen lab @UCPH_Research and Szallasi lab @BostonChildrens with important contributions from @LDyrskjot @AarhusUni , Gopa Iyer @BrendanGuercio @MSKCancerCenter , and others. .
1
0
1
Happy to share our results from a fun collaborative effort recently published in @jclinicalinvest . "Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer" . A brief overview of our findings. .
4
6
29
RT @HarvardRadOnc: Prospective applicants, come join us TOMORROW 8/12 for our open house to discuss our fabulous residency program, you won….
0
4
0
RT @BladderCancerUS: New funding opportunity! BCAN Continuity Grants provide up to $200K to support bladder cancer research interrupted by….
0
8
0
Submit your abstract today and join us in Munich for a great program!.
ONE MORE DAY! Tomorrow is the deadline to submit abstracts and travel award applications for IBCN 2025 - Munich, Germany!. @pcvblack @LDyrskjot @ttodenhoefer @Roland3097 @mouwlab @CanImmun @jdamrauer
0
4
17
Great job by Ilana E. presenting ctDNA data from our combined @DanaFarber_GU @MGHCancerCenter @BrighamRadOnc cohort of patients with MIBC treated with TMT! Post-treatment ctDNA status is highly prognostic in the TMT setting.
0
10
51
RT @DanaFarber: Bladder cancer treatment is evolving — from immunotherapy and gene therapy for early stages to research into NK cell therap….
blog.dana-farber.org
Bladder cancer treatment is advancing, two novel therapies have been recently approved for the treatment of non-muscle invasive bladder cancer. Learn more.
0
3
0
RT @KMittalmd: Unstoppable Boston: @BladderCancerUS BCAN Boston walk starting soon… @mouwlab @MattMossanen @KMittalmd .A big thank you to a….
0
2
0
